公开(公告)号：WO2022272047A1

公开(公告)日：2022-12-29

申请号：PCT/US2022/034882

申请日：2022-06-24

Applicant: ACADEMIA SINICA ,  LIU, Fu-Tong

Inventor： WU, Han-Chung ,  LEE, Chi-Chiu

IPC: C07K16/30 ,  A61K39/395 ,  A61P35/00 ,  A61K38/18 ,  A61K47/42

Abstract: The present invention relates to combined therapy of cancer using an epithelial cell adhesion molecule (EpCAM) inhibitor and a hepatocyte growth factor receptor (HGFR) inhibitor. Specifically, the EpCAM inhibitor is an antibody which is directed to an extracellular domain (EpEX) of EpCAM. The combined therapy is effective in inducing apoptosis of cancer cells, inhibiting migration/invasion of cancer cells, reducing tumor size, and/or prolonging survival of a cancer patient.

公开(公告)号：EP4359446A1

公开(公告)日：2024-05-01

申请号：EP22829373.4

申请日：2022-06-24

Applicant: Academia Sinica

Inventor： WU, Han-Chung ,  LEE, Chi-Chiu

IPC: C07K16/30 ,  A61K39/395 ,  A61P35/00 ,  A61K38/18 ,  A61K47/42

CPC classification number: A61K39/395 ,  A61P35/00 ,  C07K16/30 ,  A61K9/0019 ,  A61K9/0053 ,  A61K2039/50520130101 ,  C07K2317/7320130101 ,  A61K31/5377 ,  A61K31/4545 ,  A61K31/47